Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Morris

Showing results (261-270 of 324) with videos related to

Pageof 33
Sort By:
Cell|December 3, 2019
High-Throughput Mapping of B Cell Receptor Sequences to Antigen SpecificityIan Setliff, Andrea R Shiakolas, Kelsey A Pilewski, et al.
AIDS Research and Human Retroviruses|June 27, 2017
HIVR4P 2016, Partnering for Prevention: Conference Summary and HighlightsBarbara L Shacklett, Cynthia A Derdeyn, Morenike Oluwatoyin Folayan, et al.
Virology Journal|December 4, 2013
Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary modelsMiguel Lacerda, Penny L Moore, Nobubelo K Ngandu, et al.
Plos Pathogens|March 31, 2016
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C InfectionKshitij Wagh, Tanmoy Bhattacharya, Carolyn Williamson, et al.
Journal of Virology|January 16, 2025
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistancePaula Cohen, Bronwen E Lambson, Nonhlanhla N Mkhize, et al.
The Lancet. HIV|March 31, 2023
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trialSharana Mahomed, Nigel Garrett, Edmund V Capparelli, et al.
The Journal of Infectious Diseases|February 8, 2022
Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus PreventionSharana Mahomed, Nigel Garrett, Edmund V Capparelli, et al.
Plos Pathogens|January 12, 2017
Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral EscapeConstantinos Kurt Wibmer, Jason Gorman, Gabriel Ozorowski, et al.
Frontiers in Immunology|May 29, 2025
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccinesCassie G Ackerley, Srilatha Edupuganti, Chenchen Yu, et al.
Lancet (London, England)|December 7, 2019
The complex challenges of HIV vaccine development require renewed and expanded global commitmentLinda-Gail Bekker, Roger Tatoud, Francois Dabis, et al.
Pageof 33

Showing results (261-270 of 324) with videos related to

Sort By:
Pageof 33
Cell|December 3, 2019
High-Throughput Mapping of B Cell Receptor Sequences to Antigen SpecificityIan Setliff, Andrea R Shiakolas, Kelsey A Pilewski, et al.
AIDS Research and Human Retroviruses|June 27, 2017
HIVR4P 2016, Partnering for Prevention: Conference Summary and HighlightsBarbara L Shacklett, Cynthia A Derdeyn, Morenike Oluwatoyin Folayan, et al.
Virology Journal|December 4, 2013
Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary modelsMiguel Lacerda, Penny L Moore, Nobubelo K Ngandu, et al.
Plos Pathogens|March 31, 2016
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C InfectionKshitij Wagh, Tanmoy Bhattacharya, Carolyn Williamson, et al.
Journal of Virology|January 16, 2025
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistancePaula Cohen, Bronwen E Lambson, Nonhlanhla N Mkhize, et al.
The Lancet. HIV|March 31, 2023
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trialSharana Mahomed, Nigel Garrett, Edmund V Capparelli, et al.
The Journal of Infectious Diseases|February 8, 2022
Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus PreventionSharana Mahomed, Nigel Garrett, Edmund V Capparelli, et al.
Plos Pathogens|January 12, 2017
Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral EscapeConstantinos Kurt Wibmer, Jason Gorman, Gabriel Ozorowski, et al.
Frontiers in Immunology|May 29, 2025
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccinesCassie G Ackerley, Srilatha Edupuganti, Chenchen Yu, et al.
Lancet (London, England)|December 7, 2019
The complex challenges of HIV vaccine development require renewed and expanded global commitmentLinda-Gail Bekker, Roger Tatoud, Francois Dabis, et al.
Pageof 33